Rubén Ramos Alcocer1, José Gregorio Ledezma Rodríguez2, Antonio Navas Romero3, José Luis Cardenas Nuñez4, Vicente Rodríguez Montoya5, Jose Junior Deschamps6, Jorge Anibal Liviac Ticse7. 1. a 1 Otorrinolaringologo y Neurotologo, Medicentro del Parque , San Luis Potosí S.L.P, México. 2. b 2 ORL, Otoneurología, Fundación Venezolana de Otología, Instituto de Otorrinolaringología y Oftalmología, Hospital Militar Dr Carlos Arvelo , Caracas, Venezuela. 3. c 3 Médico Otorrinolaringólogo-Neurootólogo, Servicio de ORL, Dirección General de Aviación Civil, Director de la clínica del vértigo y acúfenos , Quito, Ecuador. 4. d 4 Profesor Titular de Neurologia, Facultad de Ciencias Médicas, Universidad de Santiago de Chile, Centro de Medicina Aeroespacial, Fuerza Aérea de Chile , Las Condes, Santiago de Chile. 5. e 5 Otorrinolaringólogo-Otólogo, Clínica del Country, Clínica La Colina , Bogotá, Colombia. 6. f 6 Centro de Otorrinolaringología y Especialidades, Universidad autónoma de Santo Domingo , República Dominicana. 7. g 7 Neurología, Clínica privada Jorge Anibal Liviac Ticse , Lima, Peru.
Abstract
CONCLUSION: Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo. OBJECTIVES: The goal of this paper is to review the pharmacological profile of betahistine and the evidence for its effectiveness and safety in the treatment of peripheral vertigo. METHODS: Selection criteria for the publications on betahistine included randomized clinical trials that evaluated the effectiveness and safety of betahistine vs placebo or active control in the treatment of peripheral vertigo. Recent meta-analyses were also included. Databases searched included PubMed, the Cochrane Ear, Nose and Throat Disorders Group Trials Register, and ICTRP. The review also presents an update on the mechanisms of action, pharmacodynamics, and pharmacokinetics of betahistine. RESULTS: Efficacy and safety of betahistine has been demonstrated in numerous clinical trials. The precise mechanism of action of betahistine is still not completely understood, but the clinical experience demonstrated the benefit of betahistine in different types of peripheral vertigo. In more than 40 years of clinical use, betahistine has shown an excellent safety profile with the usual dose range from 8-48 mg daily. According to clinical studies, betahistine 48 mg daily during 3 months is an effective and safe option for the treatment of peripheral vertigo.
CONCLUSION: Clinical studies and meta-analyses demonstrated that betahistine is effective and safe in the treatment of Ménière's disease, BPPV (benign paroxysmal positional vertigo), vestibular neuronitis, and other types of peripheral vertigo. OBJECTIVES: The goal of this paper is to review the pharmacological profile of betahistine and the evidence for its effectiveness and safety in the treatment of peripheral vertigo. METHODS: Selection criteria for the publications on betahistine included randomized clinical trials that evaluated the effectiveness and safety of betahistine vs placebo or active control in the treatment of peripheral vertigo. Recent meta-analyses were also included. Databases searched included PubMed, the Cochrane Ear, Nose and Throat Disorders Group Trials Register, and ICTRP. The review also presents an update on the mechanisms of action, pharmacodynamics, and pharmacokinetics of betahistine. RESULTS: Efficacy and safety of betahistine has been demonstrated in numerous clinical trials. The precise mechanism of action of betahistine is still not completely understood, but the clinical experience demonstrated the benefit of betahistine in different types of peripheral vertigo. In more than 40 years of clinical use, betahistine has shown an excellent safety profile with the usual dose range from 8-48 mg daily. According to clinical studies, betahistine 48 mg daily during 3 months is an effective and safe option for the treatment of peripheral vertigo.
Authors: Wan Ahmad Amiruddin Wan Hassan; Khairul Ridhwan Mohd Nasir Mohd Nasir; Saiful Adli Jamaluddin; Edre Mohammad Aidid; Yahia F Hussein Al-Hadeethi Journal: Cureus Date: 2022-06-30
Authors: Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli Journal: Int J Environ Res Public Health Date: 2021-12-08 Impact factor: 3.390